Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
Mayo Clinic
Eastern Cooperative Oncology Group
Emory University
University of Utah
NRG Oncology
NRG Oncology
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
IRCCS San Raffaele
Thomas Jefferson University
First Hospital of China Medical University
Radiation Therapy Oncology Group
City of Hope Medical Center
Fundacion IMIM
Ann & Robert H Lurie Children's Hospital of Chicago
Wake Forest University Health Sciences
OHSU Knight Cancer Institute
The Netherlands Cancer Institute
University Health Network, Toronto
Centre Georges Francois Leclerc
Samsung Medical Center
University of Nebraska
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Cancer Trials Ireland
Georgetown University
Georgetown University
Radiation Therapy Oncology Group
University of California, Davis
Radiation Therapy Oncology Group
Emory University
University of California, San Francisco
Institut Cancerologie de l'Ouest
Nanobiotix
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University Hospital, Geneva
Mayo Clinic
Abramson Cancer Center at Penn Medicine
University of Kentucky
University of Miami
University of California, San Francisco
Masonic Cancer Center, University of Minnesota
Radiation Therapy Oncology Group
Virginia Commonwealth University
National Institutes of Health Clinical Center (CC)
Institut de Cancérologie de Lorraine
University of Kansas Medical Center
AHS Cancer Control Alberta
Proton Collaborative Group
Nova Scotia Cancer Centre